Medical dermatology products specially focused on the treatment of the life-disrupting symptoms of severe dry skin conditions. Mediderm was developed to improve the quality of our patients’ lives, to ease and help eradicate the symptoms associated with psoriasis, eczema and atopic dermatitis.
All Mediderm formulations have been developed by our in-house pharmacists, are produced and quality-controlled in our GMP certified manufacturing site in Kraków, Poland.
Mediderm products have positive clinical assessments as to safety and efficacy. All have hypoallergenic formulas, with the numer of components reduced to the minimum and do not contain SLS, parabens, steroids, artificial colours or fragrances. Suitable for all ages, even small children.
- body wash 250 g
- bath oil 275 ml
- Shampoo 200 g
- Cream 100 g, 500 g, 1 kg
Mediderm® products are a complete therapy specially formulated for severe dry skin conditions such as psoriasis, eczema and atopic dermatitis.
Dermatoses and accompanying severe dry skin conditions are very common in developed countries and rising in numbers. Atopic dermatitis (AD) is one of the most common disorders affecting up to 20% of the population, depending on the country1.
Another inflammatory skin disease is psoriasis which affects around up to 5% of the population2 There is 70% risk of psoriasis if both parents are affected3.
In all dermatoses with inflamed states, the dryness and increased mitotic activity of epidermal cells are observed. The symptoms of dry skin apart from roughness may include peeling and cracking of the epidermis, lichenification or erythema4.
Topical skin treatments intended for patients affected by problems of severe skin dryness, should have a wide spectrum of activity; appropriate hydration and replenishing of the skin epidermis which will help reducing the number of used medicines, including local glucocorticosteroids (so-called steroid-sparing effects)5.
Mediderm® products and compliance
It can be difficult for patients suffering from psoriasis to find the right topical treatment product for daily use. In order to maintain compliance (observing therapy recommendation), the topical treatments, apart from effectiveness, should also be characterised by the convenience of use and efficiency.
Non-compliance with medical recommendations was observed in nearly 25% of patients using moisturising and replenishing preparations. The decisive factors were unpleasant smell, oily consistency, staining of clothing7 and price.
Mediderm® products do not contain SLS, parabens, fragrances and colour and due to their light formula are well absorbed and do not stain clothes or bedding.
The most common causes of allergies in topical treatment products are fragrances and preservatives8. The addition of moisture-locking substances (e.g. urea) can also be irritating. Mediderm® does not contain any of these irritants.
Regular use of Mediderm® products reduces irritation and allergies.
Mediderm® in complementary therapy
Glucocorticosteroids are still one of the standard therapies in the treatment of inflammatory dermatoses such as psoriasis or atopic dermatitis. Many patients (some studies say as high as 73%) may experience corticosteroid phobia9. So alternative therapies have to be available.
A good example of avoiding glucocorticosteroids is the use of complementary therapy with appropriate moisturising and replenishing preparations. Thanks to such a procedure, the following results have been achieved:
• shortening of the time of exacerbations, reducing the number of symptom recurrences and preserving the improvement after corticotherapy in psoriasis10;
• reduction of treatment time in AD11;
• significant improvement of scaly layer hydration in psoriasis12;
• significant reduction in corticosteroid consumption in children with AD13;
• reduction of the risk of tachyphylaxis with corticosteroids14.
Mediderm® products fulfil such expectations of complimentary therapy, they have a positive effect on the condition and appearance of the skin. It is important not to be limited to the periods of severe inflammation but also the use of Mediderm should be continued in periods of remission and then for prevention.
Mediderm preparations have been dermatologically tested in patients with psoriasis and AD.
Mediderm® BATH OIL and BODY WASH gently cleanse without irritation.
Baths are particularly suitable for patients with allergic dermatoses because of their moisturising effect, the ability to remove irritants, allergens and keratinized epidermis15.
Mediderm® BATH OIL and Mediderm® BODY WASH are part of the treatment of psoriasis, eczema and AD. They contain gentle cleansers that protect, moisturise and nourish at the same time without irritating the skin.
The strength of the Mediderm® products is understanding the needs of patients and their families who are struggling with psoriasis, eczema and atopic dermatitis. This is supported by the following facts:
• all preparations have been subjected to clinical evaluation with positive results;
• all preparations have a reduced number of ingredients and a hypoallergenic formula to reduce the risk of irritation as effectively as possible;
• the ingredients used in the formulations have very well documented efficacy and safety;
• the available packaging sizes allow for a prolonged and intensive usage;
• knowledge of the importance of daily moisturising and replenishing of abnormal skin.
Mediderm® products remains within the reach of every family’s budget.
Mediderm® products are a total management therapy for psoriasis, eczema and atopic dermatitis:
– cream 100g, 500g, 1kg;
– shampoo 200g;
– body wash 250g;
– bath oil 275 ml.
1. Dermatological examinations
– Each Mediderm® product (CREAM, BATH, BODY WASH and SHAMPOO) was tested on a separate group of 25 people with symptoms of allergic skin diseases.
– Mediderm® was applied to the forearm and covered with a dressing.
– Dressings were removed after 24 hours and the result of the test was read out.
– Readings were then taken on the 3rd, 4th and 5th day of the examination.
Result: negative – in all tested patients, in each group, no signs of irritation, inflammatory or allergic reactions were observed or reported by the patients.
Use and application test:
– Each Mediderm® product (cream, bath, body wash and shampoo) was tested on a separate group of 25 people with symptoms of allergic skin diseases.
– All preparations were tested for the duration of one month in accordance with the manufacturer’s recommendation.
– All patients in each group were dermatologically checked twice a week.
Result: no irritation or allergy changes were observed.
Also in addition:
– very good hydration, smoothing and elasticity of the skin was evident;
– a reduction and relief of existing irritations have been observed;
– an increase in blood supply to the skin was observed after the use of bath formula.
Tested for the presence of the following microorganisms:
– Pseudomonas aeruginosa;
– Staphylococcus aureus;
– Candida albicans;
– Oxygen mesophilic microorganisms.
1. Sybilski AJ, Raciborski F, Lipiec A, Tomaszewska A, Lusawa A, Samel-Kowalik P, Walkiewicz A, Krzych E, Komorowski J, Samoliński B. Atopic dermatitis is a serious health problem in Poland. Epidemiology studies based on ECAP study. Post Dermatol Alergol. 2013.
2. Parisi R, Symmons DPM, Griffiths CEM, Ashcroft DM, and the Identification and Management of Psoriasis and Associated ComorbidiTy (IMPACT) project team. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133(2):377–85.
3. Magdalena Czarnecka-Operacz. Dry skin as an up-to-date clinical problem. Post Dermatol Alergol 2006; XXIII, 2: 49–56.
4. Komentarz do aktualnych wytycznych terapeutycznych dotyczących atopowego zapalenia skóry. Stanowisko ekspertów Sekcji Dermatologicznej Polskiego Towarzystwa Alergologicznego i Sekcji Alergologicznej Polskiego Towarzystwa Dermatologicznego. Roman Nowicki. Lekarz POZ, 1/2015.
5. Szepietowski J., Kaszuba A., Adamski Z. i wsp.: Emolienty w leczeniu schorzeń dermatologicznych: stanowisko grupy ekspertów. Dermatol. Klin., 2011; 13: 209–214.
6. Zaleska A., Szepietowski J.: Leczenie miejscowe łuszczycy: czy chorzy stosują leki zgodnie z zaleceniami lekarskimi? Dermatologia Kliniczna 2004; 6:85-8.
7. Lodén M. Role of topical emollients and moisturizers in the treatment of dry skin barrier disorders. Am J Clin Dermatol. 2003;4(11):771-88.
8. Charman CR, Morris AD, Williams HC. Topical corticosteroid phobia in patients with atopic eczema. Br J Dermatol. 2000 May;142(5):931-6.
9. Seité S, Khemis A, Rougier A, Ortonne JP. Emollient for maintenance therapy after topical corticotherapy in mild psoriasis. Exp Dermatol. 2009 Dec;18(12):1076-8. doi: 10.1111/j.1600-0625.2009.00903.x.
10. Wanat-Krzak M, Kurzawa R. Diagnosis and treatment of atopic dermatitis. Alergia Astma Immunologia 2006, 11(1):11-21.
11. Adam Reich, Jacek Szepietowski, Izabela Zimoląg. Emolienty jako suplementacja terapii łuszczycy plackowatej propionianem klobetazolu: prospektywne badanie randomizowane. Dermatologia Kliniczna, 2006.
12. Grimalt R, Mengeaud V, Cambazard F; Study Investigators’ Group. The steroid-sparing effect of an emollient therapy in infants with atopic dermatitis: a randomized controlled study. Dermatology. 2007;214(1):61-7.
13. Kwiek B., Ambroziak M., Lagner A.: Kortykosteroidy stosowane miejscowo. Dermatologia Estetyczna vol. 5 nr 1/2003.
14. Wanat-Krzak M., Kurzawa R.: Atopowe zapalenie skóry – pierwsza manifestacja kliniczna choroby alergicznej. Terapia nr 11(158), listopad 2004.